Starton Holdings, Inc.

S-1/A amended

Range $5.00 to $7.00 · 5,000,000 shares

S-1/A amended

Range $5.00 to $7.00 · 5,000,000 shares

S-1/A amended

Range $5.00 to $7.00 · 6,666,667 shares · Gross proceeds $46,666,669

S-1/A amended

Price $6.00 · Range $5.00 to $7.00 · 6,666,667 shares

Starton Holdings, Inc. is conducting an initial public offering (IPO) of 6,666,667 shares of common stock, with an estimated price range of $5.00 to $7.00 per share. The company, a clinical-stage biotechnology firm, focuses on developing continuous delivery systems for cancer therapies using its proprietary platform. Its lead program, STAR-LLD, involves low-dose lenalidomide formulations for hematologic malignancies, while another candidate, STAR-OLZ, targets chemotherapy-induced nausea but is currently on hold. The IPO aims to fund clinical trials and expand its pipeline, with shares expected to list on Nasdaq under the symbol 'STA'.

S-1/A amended

Range $5.00 to $7.00 · 6,666,667 shares

Starton Holdings, Inc. is a pharmaceutical company focused on developing and commercializing products within a highly regulated environment. The company faces significant risks related to regulatory compliance, clinical trial outcomes, manufacturing processes, and marketing practices. Key challenges include potential FDA rejections, adverse effects from products, reliance on third-party contractors, and exposure to legal liabilities from non-compliance with healthcare regulations. The company emphasizes the importance of clinical trial success and regulatory approvals for its growth and commercialization efforts.

S-1 filed

Range $5.00 to $7.00 · 6,666,667 shares

Starton Holdings, Inc. is seeking to raise capital through an IPO to fund its pharmaceutical product development and commercialization efforts. The company faces significant risks related to clinical trial failures, regulatory approvals, manufacturing challenges, and competition. It has experienced financial losses and relies on external financing to sustain operations. The filing highlights risks associated with product development, third-party dependencies, adverse effects, and market acceptance, emphasizing the uncertainty of achieving profitability and the potential for material adverse impacts on business operations.

DRS/A amended

Starton Holdings, Inc. highlights ongoing challenges in securing sufficient financing, developing and commercializing new pharmaceutical products, and navigating regulatory approvals. The company emphasizes risks related to reliance on third-party suppliers, competition, and the uncertainty of research and development outcomes. Continued losses and dependence on external capital are recurring themes, with no significant shifts from the previous filing.

DRS filed

Starton Holdings, Inc. is seeking additional financing to support its operations and product development, given its history of operating losses and reliance on research and development. The company faces significant risks in product commercialization, including regulatory delays, competition, supply chain vulnerabilities, and the inability to secure sufficient capital. Its future profitability depends on successful FDA approvals, timely product launches, and managing development costs, with no assurance of long-term financial viability.